These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827 [TBL] [Abstract][Full Text] [Related]
26. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152 [TBL] [Abstract][Full Text] [Related]
28. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410 [TBL] [Abstract][Full Text] [Related]
29. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Byun BH; Noh WC; Lim I; Lee SS; Cho AR; Park JA; Kim KM; Kim HA; Kim EK; Kim BI; Choi CW; Lim SM Ann Nucl Med; 2013 Oct; 27(8):720-8. PubMed ID: 23700260 [TBL] [Abstract][Full Text] [Related]
31. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399 [TBL] [Abstract][Full Text] [Related]
33. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation. Im HJ; Paeng JC; Cheon GJ; Kim EE; Lee JS; Goo JM; Kang KW; Chung JK; Lee DS Nucl Med Commun; 2016 Jun; 37(6):616-22. PubMed ID: 26836629 [TBL] [Abstract][Full Text] [Related]
34. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET. Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481 [TBL] [Abstract][Full Text] [Related]
36. Speeding up PET/MR for cancer staging of children and young adults. Aghighi M; Pisani LJ; Sun Z; Klenk C; Madnawat H; Fineman SL; Advani R; Von Eyben R; Owen D; Quon A; Moseley M; Daldrup-Link HE Eur Radiol; 2016 Dec; 26(12):4239-4248. PubMed ID: 27048532 [TBL] [Abstract][Full Text] [Related]
38. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700 [TBL] [Abstract][Full Text] [Related]
39. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383 [TBL] [Abstract][Full Text] [Related]
40. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]